Economy
Daraxonrasib’s FDA Nod: A Rare Win for Pancreatic Cancer, Priced for Investors
The first targeted therapy in years extends median survival by months. Patients gain time. Pharma gains pricing power.
Index
KRAS inhibitor
1 original story in the magazine.